Phase 2 CLOVER-1 Study Shows Promise for Patients With Triple-Class Refractory Multiple Myeloma

首页> 外文期刊>Oncology >Phase 2 CLOVER-1 Study Shows Promise for Patients With Triple-Class Refractory Multiple Myeloma

【24h】

Phase 2 CLOVER-1 Study Shows Promise for Patients With Triple-Class Refractory Multiple Myeloma

机译：第2阶段三叶草-1研究显示了三类难治性多发性骨髓瘤患者的承诺

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Oncology》 |2020年第10期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma [J] . Yun Leng, Wenming Chen, Lugui Qiu, 癌症（英文版） . 2016,第012期
2. Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function [J] . Shao-long HE, Yu-hang CHENG, Di WANG, 当代医学科学(英文) . 2021,第003期
3. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH [J] . Cornell Robert, Hari Parameswaran, Tang Shijie, American Journal of Hematology . 2021,第1期

机译：用Selinexor加上塞里宁克罗宁克斯治疗三类耐火多种骨髓瘤患者的整体存活率对猛犸象的护理标准
4. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the United States [J] . Madduri Deepu, Hagiwara May, Parikh Kejal, Future oncology . 2021,第5期

机译：真实世界的治疗模式，医疗保健使用和三类中的成本暴露在美国的复发和难治性多发性骨髓瘤患者
5. Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902) [J] . Ozaki Shuji, Hata Hiroyuki, Abe Masahiro, Annals of hematology . 2016,第6期

机译：硼替佐米联合地塞米松降低频率治疗老年复发和/或难治性多发性骨髓瘤的患者：日本骨髓瘤研究小组的第二阶段研究（JMSG-0902）
6. Analysis of the secondary structure of blood serum proteins from patients with multiple myeloma [C] . M O Kobeleva, E A Telnaya, L V Plotnikova, International Conference PhysicA.SPb . 2020

机译：多发性骨髓瘤患者血清血清蛋白二次结构分析
7. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
8. Safety and efficacy of vorinostat bortezomib doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly relapsed and unfit multiple myeloma) [O] . Johannes M. Waldschmidt, Alexander Keller, Gabriele Ihorst, 2018

机译：伏立诺他硼替佐米阿霉素和地塞米松在I / II期研究中对复发或难治性多发性骨髓瘤的安全性和有效性（VERUMM研究：伏立诺他用于老年复发和不适的多发性骨髓瘤）
9. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study [O] . Jakubowiak, Andrzej J., Richardson, Paul G., Zimmerman, Todd, 2012

机译：呋喃西林加来那度胺和地塞米松治疗复发和复发/难治性多发性骨髓瘤：一期多发性骨髓瘤研究联盟研究
10. Case Control Study of Multiple Myeloma Among workers Exposed to Ionizing Radiatio211 and Other Physical and Chemical Agents [R] . 1998

机译：电离辐射和其他物理化学物质的工人多发性骨髓瘤病例对照研究

Phase 2 CLOVER-1 Study Shows Promise for Patients With Triple-Class Refractory Multiple Myeloma

著录项

相似文献

相关主题

期刊订阅